www.fiercebiotech.com

UPDATE: Pfizer's oral COVID-19 antiviral cuts hospitalization, death by 89%, sending team barreling to FDA

Pfizer’s oral COVID-19 antiviral Paxlovid has cut the risk of hospitalization or death by 89% in a late-phase trial, prompting the Big Pharma to stop the study and race to seek emergency use authorization from the FDA. Merck showed oral antivirals can make a difference in COVID-19 around one month ago, presenting late-phase data showing its candidate halved the risk of hospitalization and death.